Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia

  • D. Williams
  • M. Perri
  • M. J. Zervos


In a randomized prospective study ampicillin/sulbactam and cefamandole were compared in the therapy of patients hospitalized with community acquired pneumonia. Patients receiving ampicillin/sulbactam (n=37) and cefamandole (n=38) were similar with respect to age (mean age 70 vs. 76 years respectively), clinical characteristics, severity of illness and underlying disease. Pathogens isolated from patients in the cefamandole and ampicillin/sulbactam group, respectively, wereStreptococcus pneumoniae (7 vs. 7 patients),Haemophilus parainfluenzae (7 vs. 6 patients),Haemophilus influenzae (5 vs. 5 patients),Staphylococcus aureus (5 vs. 4 patients),Escherichia coli (4 vs. 4 patients),Klebsiella pneumoniae (3 vs. 3 patients),Enterobacter spp. (2 vs. 3 patients),Moraxella catarrhalis (1 vs. 2 patients), and organisms of the oral flora (4 vs. 3 patients). The rate of resistance to penicillin was 80 %, to clindamycin 76 %, to erythromycin 45 %, to ampicillin 43 %, and to cefazolin 18 %. Overall successful treatment rates of 81 % for cefamandole and 97 % for ampicillin/sulbactam (p=0.05) were observed. Both cefamandole and ampicillin/sulbactam were shown to be effective agents for therapy of community acquired pneumonia; however ampicillin/sulbactam demonstrated superior overall clinical efficacy.


Escherichia Coli Pneumonia Ampicillin Staphylococcus Aureus Erythromycin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Donowitz GR, Mandell GL Empiric therapy for pneumonia. Reviews of Infectious Diseases 1983, Supplement 5: 40–51.Google Scholar
  2. 2.
    Lode H Initial therapy of pneumonia. American Journal of Medicine 1986, 80 Supplement 5C: 70–74.CrossRefGoogle Scholar
  3. 3.
    Finch R, MacFarlane JT, Selkon JD, Watson J, White RJ, Winter JH, Woodhead MA Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. British Journal of Hospital Medicine 1993, 49: 346–50.PubMedGoogle Scholar
  4. 4.
    Berntsson E, Blomberg J, Lagergard T, Trollfors B Etiology of community-acquired pneumonia in patients requiring hospitalization. European Journal of Clinical Microbiology 1985, 4: 268–272.PubMedGoogle Scholar
  5. 5.
    Bently DW Bacterial pneumonia in the elderly: clinical features, diagnosis, etiology, and treatment. Gerontology 1984, 30: 297–307.PubMedGoogle Scholar
  6. 6.
    Berk SL, Wiener SL, Eisner LB, Duncan JW, Smith JK MixedStreptococcus pneumoniae and gram-negative bacillary pneumonia in the elderly. Southern Medical Journal 1981, 74: 144–146.PubMedGoogle Scholar
  7. 7.
    Dorff GJ, Rytel MW, Farmer SG, Scanlon G Etiologies and characteristic features of pneumonias in a municipal hospital. American Journal of the Medical Sciences 1973, 266: 349–358.PubMedGoogle Scholar
  8. 8.
    Ebright JR, Rytel MW Bacterial pneumonia in the elderly. Journal of American Geriatrics Society 1980, 28: 220–223.Google Scholar
  9. 9.
    Griffith DE Pneumonia in chronic lung disease. Infectious Disease Clinics of North America 1991, 5: 467–484.PubMedGoogle Scholar
  10. 10.
    Garb JL, Brown RB, Garb JR, Tuthill RW Differences in etiology of pneumonias in nursing homes and community patients. Journal of the American Medical Association 1978, 240: 2169–2172.CrossRefPubMedGoogle Scholar
  11. 11.
    Garibalidi RA Epidemiology of community-acquired respiratory tract infections in adults. American Journal of Medicine 1985, 78 Supplement 6B: 32–37.CrossRefPubMedGoogle Scholar
  12. 12.
    Karnad A, Salvador A, Berk SL Pneumonia caused by gram-negative bacilli. American Journal of Medicine 1985, 79 Supplement 1A: 61–67.CrossRefPubMedGoogle Scholar
  13. 13.
    Klimek JJ, Ajemian E, Fontecchio S, Gracewski J, Klemas B, Jimenez L Community-acquired pneumonia requiring admission to hospital. American Journal of Infection Control 1983, 11: 79–82.PubMedGoogle Scholar
  14. 14.
    MacFarlane JT, Finch RG, Ward MJ, MacRae AD Hospital study of adult community-acquired pneumonia. Lancet 1982; ii: 255–258.CrossRefGoogle Scholar
  15. 15.
    Sullivan RJ, Dowdle WB, Marine MW, Hierholzer JC Adult pneumonia in a general hospital. Archives of Internal Medicine 1972, 129: 935–942.CrossRefPubMedGoogle Scholar
  16. 16.
    Verghese A, Berk S Bacterial pneumonia in the elderly. Medicine 1983, 62: 271–285.PubMedGoogle Scholar
  17. 17.
    White RJ, Blainey AD, Harrison KJ, Clark SKR Causes of pneumonia presenting to a district general hospital. Thorax 1982, 36: 566–570.Google Scholar
  18. 18.
    Murray PR, Washington JA Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clinic Proceedings 1975, 50: 339–344.PubMedGoogle Scholar
  19. 19.
    McCabe WR, Jackson GG Gram-negative bacteremia. I: Etiology and ecology. Archives of Internal Medicine 1962, 110: 847–855.Google Scholar
  20. 20.
    National Committee for Clinical Laboratory Standards Performance standards for clinical laboratory standards. Approved Standard M7-A2, NCCLS, Villanova, PA, 1990.Google Scholar
  21. 21.
    National Committee for Clinical Laboratory Standards Performance standards for microdilution susceptibility tests. Approved Standard M2-A4. NCCLS, Villanova, PA, 1990.Google Scholar
  22. 22.
    Rhind GB, Gould GA, Ahmad F, Croughan MJ, Calder MA Haemophilus parainfluenzae andHaemophilus influenzae respiratory infections: comparison of clinical features. British Medical Journal 1985, 291: 707–708.PubMedGoogle Scholar
  23. 23.
    Foweraker JE, Cooke NJ, Hawkey PM Ecology ofHaemophilus influenzae andHaemophilus parainfluenzae in sputum and saliva and effects of antibiotics or their distribution in patients with lower respiratory tract infection. Antimicrobial Agents and Chemotherapy 1993, 37: 804–809.PubMedGoogle Scholar
  24. 24.
    Fekety FR, Caldwell J, Gump D, Johnson JE, Maxson W, Mulholland J, Thoburn R Bacteria, viruses, and mycoplasmas in acute pneumonia in adults. American Review Respiratory Disease 1971, 104: 499–507.Google Scholar
  25. 25.
    Fiala M A study of the combined role of viruses, mycoplasmas in acute pneumonia in adults. American Journal of Medicine Science 1969, 257: 44–51.Google Scholar
  26. 26.
    Larsen RA, Jacobson JA Diagnosis of community-acquired pneumonia: experience of a community hospital. Comprehensive Therapy 1984, 10: 20–25.Google Scholar
  27. 27.
    Karalus NC, Cursons RT, Leng RA, Mahood CB, Rothwell RPG, Hancock B, Cepulis S, Wawatai M, Coleman L Community acquired pneumonia: aetiology and prognostic index evaluation. Thorax 1991, 46: 413–418.PubMedGoogle Scholar
  28. 28.
    Fang GD, Fine MJ, Orloff J, Arisumi D, Yu VL, Kapoor W, Grayston JT, Wang SP, Kohler R, Muder RR, Yee YC, Rihs JD, Vickers RM New and emerging etiologies for community acquired pneumonia with implications for therapy. Medicine 1990, 69: 307–316.PubMedGoogle Scholar
  29. 29.
    Farr BM, Sloman AJ, Fisch MJ Predicting death in patients hospitalized for community-acquired pneumonia. Annals of Internal Medicine 1991, 115: 428–436.PubMedGoogle Scholar
  30. 30.
    Engle JC, Lifland PW, Schleupner CJ Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia. Antimicrobial Agents and Chemotherapy 1985, 28: 146–148.PubMedGoogle Scholar
  31. 31.
    Wallace RJ, Niefield SL, Waters S, Waters B, Awe RJ, Wiss K, Martin RR, Greenberg SB Comparative trial of cefonicid and cefamandole in the therapy of community-acquired pneumonia. Antimicrobial Agents Chemotherapy 1982, 21: 231–235.Google Scholar
  32. 32.
    Weber DJ, Calderwood SB, Karchner AW, Pennington JE Ampicillin versus cefamandole as initial therapy for community acquired pneumonia. Antimicrobial Agents Chemotherapy 1987, 31: 876–882.Google Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1994

Authors and Affiliations

  • D. Williams
    • 1
  • M. Perri
    • 1
  • M. J. Zervos
    • 1
    • 2
  1. 1.Department of Medicine, Division of Infectious DiseasesWilliam Beaumont HospitalRoyal OakUSA
  2. 2.Wayne State University School of MedicineWilliam Beaumont HospitalRoyal OakUSA

Personalised recommendations